- Home
- CZNC vs MGNX Comparison
CZNC vs MGNX Comparison
Compare CZNC & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CZNC
- MGNX
- Stock Information
- Founded
- CZNC 1864
- MGNX 2000
- Country
- CZNC United States
- MGNX United States
- Employees
- CZNC N/A
- MGNX N/A
- Industry
- CZNC Major Banks
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- CZNC Finance
- MGNX Health Care
- Exchange
- CZNC Nasdaq
- MGNX Nasdaq
- Market Cap
- CZNC 315.7M
- MGNX 257.3M
- IPO Year
- CZNC N/A
- MGNX 2013
- Fundamental
- Price
- CZNC $18.53
- MGNX $3.17
- Analyst Decision
- CZNC
- MGNX Hold
- Analyst Count
- CZNC 0
- MGNX 10
- Target Price
- CZNC N/A
- MGNX $7.17
- AVG Volume (30 Days)
- CZNC 35.2K
- MGNX 506.1K
- Earning Date
- CZNC 10-17-2024
- MGNX 11-05-2024
- Dividend Yield
- CZNC 6.04%
- MGNX N/A
- EPS Growth
- CZNC N/A
- MGNX N/A
- EPS
- CZNC 1.44
- MGNX N/A
- Revenue
- CZNC $101,899,000.00
- MGNX $141,329,000.00
- Revenue This Year
- CZNC N/A
- MGNX $174.73
- Revenue Next Year
- CZNC $7.24
- MGNX N/A
- P/E Ratio
- CZNC $12.90
- MGNX N/A
- Revenue Growth
- CZNC N/A
- MGNX 16.68
- 52 Week Low
- CZNC $16.50
- MGNX $2.95
- 52 Week High
- CZNC $23.50
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- CZNC 30.67
- MGNX 41.22
- Support Level
- CZNC $18.58
- MGNX $3.10
- Resistance Level
- CZNC $19.92
- MGNX $3.45
- Average True Range (ATR)
- CZNC 0.55
- MGNX 0.20
- MACD
- CZNC -0.24
- MGNX -0.01
- Stochastic Oscillator
- CZNC 2.42
- MGNX 17.24
About CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).